+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antihypertensive Drugs Market by Therapeutic Class, Therapy Type, Administration Route, Dosage Form, Distribution Channel, End Users - Global Forecast to 2030- Product Image
Antihypertensive Drugs Market by Therapeutic Class, Therapy Type, Administration Route, Dosage Form, Distribution Channel, End Users - Global Forecast to 2030- Product Image
Sale

Antihypertensive Drugs Market by Therapeutic Class, Therapy Type, Administration Route, Dosage Form, Distribution Channel, End Users - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715523
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antihypertensive Drugs Market grew from USD 25.76 billion in 2024 to USD 27.04 billion in 2025. It is expected to continue growing at a CAGR of 4.73%, reaching USD 34.01 billion by 2030.

Understanding the Global Antihypertensive Market Dynamics

Hypertension remains a pervasive global health challenge, affecting millions and driving a substantial need for effective pharmaceutical interventions. This executive summary distills critical insights into the current and emerging trends that are reshaping the antihypertensive drugs market. As healthcare leaders seek to improve patient outcomes while managing cost pressures, understanding the market’s key drivers, barriers, and segmentation becomes essential.

This analysis provides a structured overview of foundational market dynamics, offering clarity on the competitive environment and the forces that will influence future growth. By examining regulatory changes, technological advancements, and evolving patient needs, this summary sets the stage for deeper exploration. The report aims to equip decision-makers with actionable intelligence, empowering them to anticipate shifts, optimize portfolios, and capitalize on emerging opportunities in the antihypertensive sector.

Emerging Innovations Redefining Antihypertensive Treatment Paradigms

The landscape of antihypertensive therapies is undergoing profound transformation as therapeutic innovation converges with patient-centric care models. Precision medicine initiatives are enabling clinicians to tailor drug regimens based on genetic and biomarker profiles, enhancing efficacy while minimizing adverse effects. Concurrently, digital health platforms and remote patient monitoring tools are facilitating real-time blood pressure tracking, driving adherence and enabling early intervention.

Regulatory frameworks are evolving to expedite approval pathways for novel mechanisms of action, particularly in first-in-class agents targeting pathways beyond the renin-angiotensin-aldosterone system. Partnerships between pharmaceutical companies and technology firms are accelerating the development of combination therapies paired with digital adherence solutions. These transformative shifts underscore a move toward integrated treatment ecosystems that place the patient at the center of care delivery.

Navigating the 2025 US Tariff Adjustments and Their Market Ramifications

In 2025, newly imposed tariffs on key pharmaceutical imports into the United States have introduced notable cost pressures that ripple through supply chains and pricing structures. Raw materials sourced from tariff-affected regions have seen margin compression, compelling manufacturers to explore alternative sourcing strategies and optimize production footprints. In response, several domestic and international players have increased investment in local manufacturing capacity to mitigate exposure to import levies.

These tariff-driven shifts have also influenced collaboration models, with companies forming strategic alliances for shared production facilities and co-marketing arrangements to distribute risk. While price increases at the patient level have been limited by reimbursement negotiations, payers are increasingly scrutinizing manufacturer cost structures and demanding greater transparency. Overall, the cumulative impact of the 2025 tariff adjustments is driving a realignment of supply networks, procurement practices, and competitive positioning across the US market.

Decoding Market Segmentation to Uncover Targeted Growth Pathways

A deep dive into market segmentation reveals nuanced opportunities across multiple dimensions. When examining therapeutic class, traditional categories such as ACE inhibitors and angiotensin receptor blockers remain dominant, yet new entrants in renin inhibition and next-generation vasodilators are gaining traction. Within ACE inhibitors, familiar molecules like enalapril and lisinopril continue to anchor portfolios, while perindopril and ramipril complement efforts to capture differentiated patient groups.

Therapy type segmentation distinguishes between monotherapy and combination regimens, where dual- and triple-combination products are accelerating adoption to address resistant hypertension. Route of administration further segments the market into injectable formats-delivered intramuscularly, intravenously or subcutaneously-and oral options spanning capsules, solutions, powders and tablets, each catering to distinct clinical settings and patient preferences. Dosage form analysis underscores the ongoing relevance of capsules and tablets, alongside tailored injection solutions for acute care.

Distribution channels reflect a broad spectrum from hospital pharmacy networks, encompassing private and public institutions, to online platforms led by aggregators and direct-to-consumer operators, as well as traditional retail pharmacy formats including chain and independent outlets. Finally, end-user segmentation highlights the roles of primary and specialty clinics, homecare environments with self-medication and supervised care models, and hospital settings that span private and public institutions. This layered segmentation framework informs targeted strategies for product development, channel engagement and customer outreach.

Regional Market Nuances Shaping Strategic Priorities

Regional dynamics paint a varied yet complementary portrait of market potential. In the Americas, mature healthcare infrastructures and established reimbursement ecosystems continue to drive steady demand for both branded and generic antihypertensive therapies. Market saturation in certain segments has prompted innovators to focus on differentiated delivery systems and value-added services to sustain growth.

Across Europe, the Middle East and Africa, regulatory harmonization efforts within the European Union contrast with heterogeneous access challenges in emerging markets of North Africa and the Gulf region. Payers in Western Europe are prioritizing cost-effectiveness, prompting manufacturers to generate robust real-world evidence. Meanwhile, growth in sub-Saharan and Middle Eastern markets is catalyzed by rising health awareness and expanding clinic networks.

The Asia-Pacific region is characterized by rapid expansion in urbanized centers, where rising prevalence of hypertension intersects with increasing healthcare spending. Local manufacturers in countries such as China and India are intensifying competition through aggressive generic launches, while regulatory reforms in markets like Japan and Australia are opening pathways for novel agents. Together, these regional variances underscore the importance of tailored market entry and expansion strategies.

Competitive Strategies and Partnerships Driving Market Leadership

Leading pharmaceutical companies are executing a blend of organic innovation and strategic partnerships to fortify their antihypertensive portfolios. Established players have accelerated lifecycle management through incremental drug reformulations and extended-release technologies. Simultaneously, mid-sized firms are carving niches with specialized combination therapies and digital adherence tools.

Collaborations between large-cap manufacturers and biotechnology startups are fostering a pipeline of first-in-class candidates, particularly in the renin-inhibitor category. Companies are also pursuing acquisitions to secure proprietary drug delivery platforms and bolster geographic footprint in high-growth markets. Investment in pharmacovigilance and real-world evidence generation has become a point of differentiation, enabling sponsors to strengthen value propositions with payers and healthcare providers.

Strategic alliances extend to contract development and manufacturing organizations, allowing for flexible capacity scaling in response to shifting demand. This convergence of capabilities facilitates faster time to market and optimizes cost structures, positioning these companies to navigate evolving regulatory and commercial landscapes.

Strategic Imperatives for Sustained Competitive Advantage

Industry leaders should prioritize the development of integrated therapy solutions that combine pharmacological innovation with digital health capabilities. By investing in predictive analytics and remote monitoring platforms, organizations can enhance patient adherence and demonstrate measurable outcomes. Strategic expansion into underserved regions with customized access programs will unlock new revenue streams while addressing global health disparities.

Supply chain resilience must be fortified through diversification of manufacturing sites and raw material sourcing, mitigating the impact of geopolitical shifts and tariff fluctuations. Companies should also deepen collaborations with payers to secure value-based contracts that align reimbursement with real-world performance metrics. Portfolio optimization through the lifecycle management of legacy products alongside pipeline acceleration of differentiated candidates will sustain long-term growth.

Finally, fostering cross-functional teams that integrate clinical, regulatory and commercial expertise will streamline market entry and adoption efforts. By aligning internal capabilities with external partnerships, industry leaders can capitalize on emerging opportunities and maintain a competitive edge.

Rigorous Methodology Underpinning Strategic Insights

This analysis employs a rigorous multi-stage research methodology combining both primary and secondary research. Secondary sources include peer-reviewed journals, regulatory filings, industry reports and financial disclosures. These inputs were synthesized to establish a comprehensive baseline of market structure, competitive dynamics and regulatory landscapes.

Primary research entailed in-depth interviews with key opinion leaders, healthcare providers, payers and industry executives to validate market hypotheses and uncover nuanced insights. Quantitative data was triangulated across multiple sources to enhance reliability, while qualitative feedback provided contextual understanding of emerging trends.

Data analysis leveraged thematic coding and advanced statistical techniques to identify correlation patterns and segmentation drivers. The research process incorporated iterative peer review and stakeholder validation to ensure accuracy and relevance. This robust approach underpins the strategic recommendations and conclusions presented herein.

Synthesizing Insights to Navigate a Dynamic Market

The antihypertensive drugs market is at a pivotal juncture where innovation, regulation and patient-centric care intersect to define future trajectories. By understanding the intricate interplay of tariff impacts, segmentation nuances and regional dynamics, stakeholders can craft strategies that address both current needs and emerging opportunities.

Leading companies will leverage integrated data analytics and collaborative partnerships to accelerate product differentiation and market access. Regions with variable regulatory landscapes demand tailored approaches that balance cost pressures with local healthcare priorities. As the market continues to evolve, a disciplined focus on evidence generation, supply chain resilience and digital integration will distinguish successful players.

This report equips decision-makers with a clear roadmap to navigate complexity, embrace innovation and drive sustainable growth. The insights presented here form a strategic foundation for informed investment, deployment of resources and long-term value creation in the global antihypertensive drugs market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Class
    • Ace Inhibitors
      • Enalapril
      • Lisinopril
      • Perindopril
      • Ramipril
    • Angiotensin Receptor Blockers
      • Candesartan
      • Irbesartan
      • Losartan
      • Telmisartan
      • Valsartan
    • Beta Blockers
      • Atenolol
      • Bisoprolol
      • Metoprolol
      • Propranolol
    • Calcium Channel Blockers
      • Amlodipine
      • Diltiazem
      • Felodipine
      • Verapamil
    • Diuretics
      • Loop
      • Osmotic
      • Potassium Sparing
      • Thiazide
    • Renin Inhibitors
      • Aliskiren
    • Vasodilators
      • Diazoxide
      • Hydralazine
      • Minoxidil
  • Therapy Type
    • Combination Therapy
      • Dual Combination
      • Triple Combination
    • Monotherapy
  • Administration Route
    • Injectable
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Oral
      • Capsules
      • Oral Solutions
      • Powders
      • Tablets
  • Dosage Form
    • Capsules
    • Injections
    • Oral Solutions
    • Tablets
  • Distribution Channel
    • Hospital Pharmacies
      • Private Hospitals
      • Public Hospitals
    • Online Pharmacies
      • Aggregators
      • Direct To Consumer
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End Users
    • Clinics
      • Primary Care Clinics
      • Specialty Clinics
    • Homecare
      • Self Medication
      • Supervised Care
    • Hospitals
      • Private Hospitals
      • Public Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antihypertensive Drugs Market, by Therapeutic Class
8.1. Introduction
8.2. Ace Inhibitors
8.2.1. Enalapril
8.2.2. Lisinopril
8.2.3. Perindopril
8.2.4. Ramipril
8.3. Angiotensin Receptor Blockers
8.3.1. Candesartan
8.3.2. Irbesartan
8.3.3. Losartan
8.3.4. Telmisartan
8.3.5. Valsartan
8.4. Beta Blockers
8.4.1. Atenolol
8.4.2. Bisoprolol
8.4.3. Metoprolol
8.4.4. Propranolol
8.5. Calcium Channel Blockers
8.5.1. Amlodipine
8.5.2. Diltiazem
8.5.3. Felodipine
8.5.4. Verapamil
8.6. Diuretics
8.6.1. Loop
8.6.2. Osmotic
8.6.3. Potassium Sparing
8.6.4. Thiazide
8.7. Renin Inhibitors
8.7.1. Aliskiren
8.8. Vasodilators
8.8.1. Diazoxide
8.8.2. Hydralazine
8.8.3. Minoxidil
9. Antihypertensive Drugs Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.2.1. Dual Combination
9.2.2. Triple Combination
9.3. Monotherapy
10. Antihypertensive Drugs Market, by Administration Route
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.2.3. Subcutaneous
10.3. Oral
10.3.1. Capsules
10.3.2. Oral Solutions
10.3.3. Powders
10.3.4. Tablets
11. Antihypertensive Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsules
11.3. Injections
11.4. Oral Solutions
11.5. Tablets
12. Antihypertensive Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.2.1. Private Hospitals
12.2.2. Public Hospitals
12.3. Online Pharmacies
12.3.1. Aggregators
12.3.2. Direct To Consumer
12.4. Retail Pharmacies
12.4.1. Chain Pharmacies
12.4.2. Independent Pharmacies
13. Antihypertensive Drugs Market, by End Users
13.1. Introduction
13.2. Clinics
13.2.1. Primary Care Clinics
13.2.2. Specialty Clinics
13.3. Homecare
13.3.1. Self Medication
13.3.2. Supervised Care
13.4. Hospitals
13.4.1. Private Hospitals
13.4.2. Public Hospitals
14. Americas Antihypertensive Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antihypertensive Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antihypertensive Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Pfizer Inc.
17.3.3. AstraZeneca PLC
17.3.4. Sanofi S.A.
17.3.5. Merck & Co., Inc.
17.3.6. Boehringer Ingelheim International GmbH
17.3.7. Bayer AG
17.3.8. GlaxoSmithKline plc
17.3.9. Teva Pharmaceutical Industries Ltd.
17.3.10. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ENALAPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PERINDOPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RAMIPRIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CANDESARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY IRBESARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TELMISARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VALSARTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY AMLODIPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DILTIAZEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FELODIPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VERAPAMIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY LOOP, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY OSMOTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY POTASSIUM SPARING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THIAZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ALISKIREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HYDRALAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY MINOXIDIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DUAL COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TRIPLE COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY AGGREGATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SELF MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SUPERVISED CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 141. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 142. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 144. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 145. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 146. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 147. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 149. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 150. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 152. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 153. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 155. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 157. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 158. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 160. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 161. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 162. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 163. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 169. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 173. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 175. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 176. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 177. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 184. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 216. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 224. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 226. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 228. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 275. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 277. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 278. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 279. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 280. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 282. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 283. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 284. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 285. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 286. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 287. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 288. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 290. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 292. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 293. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 295. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 297. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 299. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 300. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 301. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, 2018-2030 (USD MILLION)
TABLE 302. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 304. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 305. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 306. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 307. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 308. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 309. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 310. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 312. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 313. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 314. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 315. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 316. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 317. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 318. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 319. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ACE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 320. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2030 (USD MILLION)
TABLE 321. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 322. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2030 (USD MILLION)
TABLE 323. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY

Companies Mentioned

The companies profiled in this Antihypertensive Drugs market report include:
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 27.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 34.01 Billion
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antihypertensive Drugs Market Report by Therapeutic Class, Type, Distribution Channel, and Region 2024-2032 - Product Image

Antihypertensive Drugs Market Report by Therapeutic Class, Type, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Antihypertensive Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Antihypertensive Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030 - Product Image

Cardiovascular Therapeutics Market by Therapy Type, End User, Application, Delivery Mode - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F - Product Image

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
North America ACE Inhibitors Market, By Country, Competition, Forecast & Opportunities, 2019-2029F - Product Image

North America ACE Inhibitors Market, By Country, Competition, Forecast & Opportunities, 2019-2029F

  • Report
  • 136 Pages
  • North America
From

About the Antihypertensive Market

The Antihypertensive market is a subset of the Cardiovascular Drugs market, which focuses on medications used to treat high blood pressure. These drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular diseases. Antihypertensives work by blocking the action of certain hormones, such as angiotensin II, which cause blood vessels to constrict. Common classes of antihypertensives include diuretics, beta blockers, ACE inhibitors, calcium channel blockers, and angiotensin receptor blockers. The Antihypertensive market is highly competitive, with many large pharmaceutical companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Other companies, such as AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo, also offer antihypertensive medications. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.